New CAR-T therapy targets Hard-to-Treat cancers in early trial
NCT ID NCT06821048
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called PTC13, which uses specially engineered immune cells (CAR-T cells) to attack cancer cells that have a protein called CEA. The study includes 18 adults with advanced colorectal, stomach, pancreatic, or other solid tumors that have not responded to standard treatments. The main goals are to check the safety of the therapy and find the best dose for future studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU)
RECRUITINGHangzhou, Zhejiang, 310006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- Can a simple CT scan catch lung cancer earlier in kuwait?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a new drug combo revive Immunotherapy's power against resistant tumors?